These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17627560)

  • 1. PCI and stable coronary heart disease--COURAGE to change our minds?
    Kakafika AI; Mikhailidis DP; Wierzbicki AS; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2007 Jul; 5(3):173-4. PubMed ID: 17627560
    [No Abstract]   [Full Text] [Related]  

  • 2. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Coronary stents: a health system perspective.
    Ahmad M
    Am Heart J; 1999 May; 137(5):S142-4. PubMed ID: 10220618
    [No Abstract]   [Full Text] [Related]  

  • 3. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Coronary stents: an industry perspective.
    Marshall PR
    Am Heart J; 1999 May; 137(5):S138-41. PubMed ID: 10220617
    [No Abstract]   [Full Text] [Related]  

  • 4. Should use of intracoronary stents during percutaneous revascularisation be restricted?
    Palmer N; Fort S; Starkey I; Shaw T; Northridge D
    Lancet; 1998 Feb; 351(9100):416-7. PubMed ID: 9482299
    [No Abstract]   [Full Text] [Related]  

  • 5. [Heart catheter in stable coronary heart disease. Drugs are equally effective].
    Einecke D
    MMW Fortschr Med; 2007 Apr; 149(15):10, 12. PubMed ID: 17668771
    [No Abstract]   [Full Text] [Related]  

  • 6. Funding of coronary angioplasty and coronary stenting in public hospitals.
    Harper RW
    Aust N Z J Med; 1996 Feb; 26(1):3-4. PubMed ID: 8775519
    [No Abstract]   [Full Text] [Related]  

  • 7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluation of the cost-effectiveness of coronary stenting: a societal perspective.
    Cohen DJ
    Am Heart J; 1999 May; 137(5):S133-7. PubMed ID: 10220616
    [No Abstract]   [Full Text] [Related]  

  • 8. DES editorial. Is there a survival benefit?
    Thomas DM
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):644-5. PubMed ID: 18360857
    [No Abstract]   [Full Text] [Related]  

  • 9. Common sense, dollars and cents, and drug-eluting stents.
    Vaitkus PT
    J Am Coll Cardiol; 2006 Jul; 48(2):268-9. PubMed ID: 16843173
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cost analysis of percutaneous coronary intervention and coronary artery bypass grafting in Japan and USA].
    Chino M; Sasaki T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():632-7. PubMed ID: 12735043
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute and long-term cost implications of coronary stenting.
    Peterson ED; Cowper PA; DeLong ER; Zidar JP; Stack RS; Mark DB
    J Am Coll Cardiol; 1999 May; 33(6):1610-8. PubMed ID: 10334432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immediate impact of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial on the management of stable angina.
    Atwater BD; Oujiri J; Wolff MR
    Clin Cardiol; 2009 Aug; 32(8):E1-3. PubMed ID: 19536842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of sirolimus-eluting stents.
    Shrive FM; Manns BJ; Galbraith PD; Knudtson ML; Ghali WA;
    CMAJ; 2005 Feb; 172(3):345-51. PubMed ID: 15684117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current indications for percutaneous coronary intervention for chronic stable angina: implications of the COURAGE Trial.
    Kiernan TJ; Prasad A; Gersh BJ
    Rev Cardiovasc Med; 2007; 8(4):234-9. PubMed ID: 18192947
    [No Abstract]   [Full Text] [Related]  

  • 15. PCI in small vessels: the case for a drug-coated balloon based intervention.
    Zeymer U; Scheller B
    EuroIntervention; 2011 May; 7 Suppl K():K57-60. PubMed ID: 22027729
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil.
    Polanczyk CA; Wainstein MV; Ribeiro JP
    Arq Bras Cardiol; 2007 Apr; 88(4):464-74. PubMed ID: 17546279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina.
    Zhang Z; Kolm P; Boden WE; Hartigan PM; Maron DJ; Spertus JA; O'Rourke RA; Shaw LJ; Sedlis SP; Mancini GB; Berman DS; Dada M; Teo KK; Weintraub WS
    Circ Cardiovasc Qual Outcomes; 2011 Mar; 4(2):172-82. PubMed ID: 21304091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resource allocation for chronic stable angina: a systematic review of effectiveness, costs and cost-effectiveness of alternative interventions.
    Sculpher MJ; Petticrew M; Kelland JL; Elliott RA; Holdright DR; Buxton MJ
    Health Technol Assess; 1998; 2(10):i-iv, 1-176. PubMed ID: 9812243
    [No Abstract]   [Full Text] [Related]  

  • 19. PCI or CABG: which patients and at what cost?
    Gershlick T; Thomas M
    Heart; 2007 Oct; 93(10):1188-90. PubMed ID: 17890695
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparing cost aspects of coronary artery bypass graft surgery with coronary artery stenting.
    Birim Ö; Bogers AJ; Kappetein AP
    J Cardiovasc Surg (Torino); 2012 Oct; 53(5):641-50. PubMed ID: 22252542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.